| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $999,853 ) |
| | 2024 | 2024 | MOLECULAR EXPRESS, INC | 2630 HOMESTEAD PL | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44HL172526 | Preclinical Development of a ME-1001, a Synthetic Lung Surfactant | 000 | 1 | NIH | 5/8/2024 | $999,853 |
| | 2024 | 2022 | MOLECULAR EXPRESS, INC | 2630 HOMESTEAD PL | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44HL154968 | Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | 000 | 2 | NIH | 2/8/2024 | $0 |
| | 2024 | 2022 | MOLECULAR EXPRESS, INC | 2630 HOMESTEAD PL | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI167394 | Niclosamide Formulations for the Treatment of Influenza Infections | 000 | 1 | NIH | 3/27/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $299,779 ) |
| | 2023 | 2023 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI167312 | VesiVax Vaccine Formulation Against Neisseria gonorrhoeae | 000 | 2 | NIH | 1/13/2023 | $299,779 |
|
| Issue Date FY: 2022 ( Subtotal = $1,810,685 ) |
| | 2022 | 2022 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44HL154968 | Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | 001 | 2 | NIH | 7/28/2022 | $67,200 |
| | 2022 | 2022 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44HL154968 | Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | 000 | 2 | NIH | 6/6/2022 | $1,031,789 |
| | 2022 | 2022 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44HL154968 | Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | 002 | 2 | NIH | 8/1/2022 | $113,400 |
| | 2022 | 2022 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI167394 | Niclosamide Formulations for the Treatment of Influenza Infections | 000 | 1 | NIH | 7/8/2022 | $298,479 |
| | 2022 | 2022 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI167312 | VesiVax Vaccine Formulation Against Neisseria gonorrhoeae | 000 | 1 | NIH | 2/17/2022 | $299,817 |
|
| Issue Date FY: 2021 ( Subtotal = $956,889 ) |
| | 2021 | 2021 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44HL154968 | Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | 000 | 1 | NIH | 6/16/2021 | $956,889 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44AI115828 | Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | 000 | 3 | NIH | 4/14/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2017 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44AI094770 | The VesiVax? System: Vaccine Development Made Easy | 000 | 4 | NIH | 1/14/2019 | $0 |
| | 2019 | 2017 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI131788 | VesiVax? Peanut Allergy Immunotherapy | 000 | 1 | NIH | 4/18/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $497,338 ) |
| | 2018 | 2018 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44AI115828 | Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | 000 | 3 | NIH | 6/26/2018 | $497,338 |
| | 2018 | 2016 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI124725 | Optimization of VesiVax? Lipidated Tucaresol Formulations | 000 | 1 | NIH | 8/28/2018 | $0 |
| | 2018 | 2015 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R42DA040422 | Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | 000 | 1 | NIH | 1/9/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,971,203 ) |
| | 2017 | 2017 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44AI094770 | The VesiVax? System: Vaccine Development Made Easy | 000 | 4 | NIH | 7/14/2017 | $736,747 |
| | 2017 | 2017 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R44AI115828 | Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | 000 | 2 | NIH | 6/28/2017 | $934,456 |
| | 2017 | 2017 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI131788 | VesiVax? Peanut Allergy Immunotherapy | 000 | 1 | NIH | 2/7/2017 | $300,000 |
| | 2017 | 2016 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R42DA040422 | Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | 001 | 1 | NIH | 1/20/2017 | $0 |
| | 2017 | 2015 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R41TR001338 | Development of a Gene and Oligonucleotide Delivery System | 001 | 1 | NIH | 6/6/2017 | $0 |
| | 2017 | 2015 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI118123 | Design and Engineering of Nanoparticulate Universal Vaccines | 000 | 1 | NIH | 11/15/2016 | $0 |
| | 2017 | 2015 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R41TR001338 | Development of a Gene and Oligonucleotide Delivery System | 000 | 1 | NIH | 11/2/2016 | $0 |
| | 2017 | 2015 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI115828 | Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | 000 | 1 | NIH | 11/15/2016 | $0 |
| | 2017 | 2015 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R42DA040422 | Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | 000 | 1 | NIH | 1/20/2017 | $0 |
| | 2017 | 2014 | MOLECULAR EXPRESS INC | 2630 HOMESTEAD PLACE | RANCHO DOMINGUEZ | CA | 90220-5610 | LOS ANGELES | USA | R43AI104073 | Novel VLP Adjuvant based on the VesiVax system | 000 | 2 | NIH | 1/11/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,082,396 ) |
| | 2016 | 2016 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R42DA040422 | Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | 000 | 1 | NIH | 7/29/2016 | $95,143 |
| | 2016 | 2016 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R44AI094770 | The VesiVax? System: Vaccine Development Made Easy | 000 | 3 | NIH | 7/20/2016 | $762,253 |
| | 2016 | 2016 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI124725 | Optimization of VesiVax? Lipidated Tucaresol Formulations | 000 | 1 | NIH | 3/15/2016 | $225,000 |
|
| Issue Date FY: 2015 ( Subtotal = $1,168,153 ) |
| | 2015 | 2015 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R42DA040422 | Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | 000 | 1 | NIH | 9/1/2015 | $225,033 |
| | 2015 | 2015 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI115828 | Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | 000 | 1 | NIH | 6/15/2015 | $329,911 |
| | 2015 | 2015 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R41TR001338 | Development of a Gene and Oligonucleotide Delivery System | 000 | 1 | NIH | 8/20/2015 | $322,946 |
| | 2015 | 2015 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI118123 | Design and Engineering of Nanoparticulate Universal Vaccines | 000 | 1 | NIH | 6/10/2015 | $290,263 |
|
| Issue Date FY: 2014 ( Subtotal = $1,597,089 ) |
| | 2014 | 2014 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI112132 | Engineering of a Novel CDN Nanoparticle Platform | 001 | 1 | NIH | 7/28/2014 | $245,943 |
| | 2014 | 2014 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI112132 | Engineering of a Novel CDN Nanoparticle Platform | 000 | 1 | NIH | 6/19/2014 | $245,943 |
| | 2014 | 2014 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI112132 | Engineering of a Novel CDN Nanoparticle Platform | 001 | 1 | NIH | 7/28/2014 | -$245,943 |
| | 2014 | 2014 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R43AI104073 | Novel VLP Adjuvant based on the VesiVax system | 000 | 2 | NIH | 7/17/2014 | $299,999 |
| | 2014 | 2014 | MOLECULAR EXPRESS, INC | 1381 WARNER AVE, SUITE C | TUSTIN | CA | 90061 | | USA | R44HL080775 | Development of a novel SP-B peptide lung surfactant | 000 | 6 | NIH | 8/16/2014 | $1,051,147 |
|
| Issue Date FY: 2013 ( Subtotal = $2,045,840 ) (Continued on the next page) |
|
